Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05504837 · ClinicalTrials.gov registry record · Phase 1

A Study Assessing KB407 for the Treatment of Cystic Fibrosis

A Phase 1 study of Cystic Fibrosis, sponsored by Krystal Biotech.

Recruiting
Registry status
Phase 1
Development phase
12
Enrollment target
5
Study locations

NCT05504837: Recruiting Phase 1 study of Cystic Fibrosis, sponsored by Krystal Biotech.

NCT05504837 is a Phase 1 study of Cystic Fibrosis that is actively recruiting participants, run by Krystal Biotech. The registered enrollment target is 12 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (93% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05504837, a Phase 1 study of Cystic Fibrosis, is actively recruiting participants, sponsored by Krystal Biotech.

RECRUITING
Registry status
Phase 1
Development phase
12 participants
Enrollment target
5
Study locations

Study Summary

This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.

Primary Outcome

Number of adult subjects with treatment related adverse events as assessed by NCI-CTCAE v5

Conditions Studied

Cystic Fibrosis

Interventions

  • BIOLOGICAL KB407 (Nebulization)

Study Locations (5)

New York

  • New York Medical College/ Boston Children's Health Physicians - Hawthorne
  • Northwell Health Physicians - New York

Florida

  • University of Florida, Gainesville - Gainesville

Illinois

  • The Cystic Fibrosis Institute - Northfield

North Carolina

  • Atrium Health Wake Forest Baptist Medical Center - Winston-Salem

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2023-06-30
Est. Completion 2026-01
Phase Phase 1
Krystal Biotech

13 total trials

What NCT05504837 shows while recruiting

NCT05504837 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which KB407 (Nebulization) is the first listed.

NCT05504837 lists 5 locations in 4 states (New York, Florida, Illinois).

Frequently Asked Questions

What is clinical trial NCT05504837 about?

NCT05504837 is a clinical study titled "A Study Assessing KB407 for the Treatment of Cystic Fibrosis". This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.

What is the current status of trial NCT05504837?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2023-06-30. Estimated completion is 2026-01.

What conditions does trial NCT05504837 study?

This clinical trial studies the following conditions: Cystic Fibrosis.

What interventions are being tested in trial NCT05504837?

The interventions under investigation include: KB407 (Nebulization) (BIOLOGICAL).

Who is sponsoring clinical trial NCT05504837?

This trial is sponsored by Krystal Biotech, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05504837 being conducted?

This trial has 5 study locations across Florida, Illinois, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cystic Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05504837's enrollment target sits among peer trials

12 152nd of 169 higher than 15 of 169 other Cystic Fibrosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05504837

Source: ClinicalTrials.gov NCT05504837, the US trial registry maintained by the National Library of Medicine. NCT05504837 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.